Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Metadata
Title
memo: Official journal of the OeGHO and CECOG
Authors
UIrich Jäger
Christoph C. Zielinski, MD
Publication date
01-02-2017
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2017
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0316-6

Other articles of this Issue 1/2017

memo - Magazine of European Medical Oncology 1/2017 Go to the issue

short review

Milestones in myeloma

short review

Milestones of the last 10 years

short review

Milestones in advanced renal cell carcinoma

short review

Milestones in the systemic treatment of lung cancer

comment

My personal highlights of ESMO 2016

short review

Breast cancer milestones 2007–2016
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits